Volodymyr I. Pidoplichko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Volodymyr I. Pidoplichko has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Maria F. M. Braga
Department of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
10 shared publications - Taiza H. Figueiredo
Department of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
9 shared publications - Vassiliki Aroniadou-Anderjaska
Department of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
8 shared publications - James P. Apland
Neuroscience Branch, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Aberdeen, MD 21010, USA
3 shared publications - Lucille A. Lumley
Neuroscience Department U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) Aberdeen Proving Ground Maryland USA
3 shared publications - Eric M. Prager
John Wiley & Sons, Inc., Hoboken, New Jersey
2 shared publications
Latest Publications
- Open Access
Persistently Elevated Gamma Power and Delayed Brain Damage in Aged Rats Acutely Exposed to Soman Without Status Epilepticus: Comparisons with Seizing Rats Treated with Midazolam or with Tezampanel and Caramiphen
Aged animals or humans are more susceptible to permanent brain damage from status epilepticus (SE), making the selection of antiseizure medication even more crucial. This study compared the antiseizure and neuroprotective efficacy of midazolam with that of tezampanel combined with caramiphen in treating soman-induced SE in aged rats. A substantial proportion of soman-exposed aged rats did not develop SE, allowing us to also study this noSE group. SE duration within 24 h post-exposure was significantly longer in the midazolam than the tezampanel + caramiphen group, which was reflected in the EEG power integral. Spectral density analysis showed sustained increase in gamma-band power in the noSE group. Increased delta power in the SE groups lasted longer after midazolam. Body temperature decreased substantially only in the noSE and tezampanel + caramiphen groups. The midazolam group displayed severe neuropathology in the hippocampus and the amygdala 7 days to 6 months post-exposure, whereas the noSE and tezampanel + caramiphen groups exhibited only delayed amygdala damage. Thus, tezampanel + caramiphen has far superior neuroprotective efficacy than midazolam in aged rats. Increased gamma power is associated with seizure resistance; however, even in the absence of SE, delayed neuropathology can develop after a single acute organophosphate exposure.
Open AccessPersistently Elevated Gamma Power and Delayed Brain Damage in Aged Rats Acutely Exposed to Soman Without Status Epilepticus: Comparisons with Seizing Rats Treated with Midazolam or with Tezampanel and Caramiphen
Aged animals or humans are more susceptible to permanent brain damage from status epilepticus (SE), making the selection of antiseizure medication even more crucial. This study compared the antiseizure and neuroprotective efficacy of midazolam with that of tezampanel combined with caramiphen in treating soman-induced SE in aged rats. A substantial proportion of soman-exposed aged rats did not develop SE, allowing us to also study this noSE group. SE duration within 24 h post-exposure was significantly longer in the midazolam than the tezampanel + caramiphen group, which was reflected in the EEG power integral. Spectral density analysis showed sustained increase in gamma-band power in the noSE group. Increased delta power in the SE groups lasted longer after midazolam. Body temperature decreased substantially only in the noSE and tezampanel + caramiphen groups. The midazolam group displayed severe neuropathology in the hippocampus and the amygdala 7 days to 6 months post-exposure, whereas the noSE and tezampanel + caramiphen groups exhibited only delayed amygdala damage. Thus, tezampanel + caramiphen has far superior neuroprotective efficacy than midazolam in aged rats. Increased gamma power is associated with seizure resistance; however, even in the absence of SE, delayed neuropathology can develop after a single acute organophosphate exposure.
- Open Access
- 6 August 2024
- Published by Elsevier in Neurobiology of Disease
- Vol. 200, 106633
Alterations in GABAA receptor-mediated inhibition triggered by status epilepticus and their role in epileptogenesis and increased anxiety
- 6 August 2024
- Published by Elsevier in Neurobiology of Disease
- Vol. 200, 106633
Open AccessAlterations in GABAA receptor-mediated inhibition triggered by status epilepticus and their role in epileptogenesis and increased anxiety
- Top Cited PapersOpen Access
Mechanisms of Organophosphate Toxicity and the Role of Acetylcholinesterase Inhibition
Organophosphorus compounds (OPs) have applications in agriculture (e.g., pesticides), industry (e.g., flame retardants), and chemical warfare (nerve agents). In high doses or chronic exposure, they can be toxic or lethal. The primary mechanism, common among all OPs, that initiates their toxic effects is the inhibition of acetylcholinesterase. In acute OP exposure, the subsequent surge of acetylcholine in cholinergic synapses causes a peripheral cholinergic crisis and status epilepticus (SE), either of which can lead to death. If death is averted without effective seizure control, long-term brain damage ensues. This review describes the mechanisms by which elevated acetylcholine can cause respiratory failure and trigger SE; the role of the amygdala in seizure initiation; the role of M1 muscarinic receptors in the early stages of SE; the neurotoxic pathways activated by SE (excitotoxicity/Ca++ overload/oxidative stress, neuroinflammation); and neurotoxic mechanisms linked to low-dose, chronic exposure (Ca++ dyshomeostasis/oxidative stress, inflammation), which do not depend on SE and do not necessarily involve acetylcholinesterase inhibition. The evidence so far indicates that brain damage from acute OP exposure is a direct result of SE, while the neurotoxic mechanisms activated by low-dose chronic exposure are independent of SE and may not be associated with acetylcholinesterase inhibition.
Top Cited PapersOpen AccessMechanisms of Organophosphate Toxicity and the Role of Acetylcholinesterase Inhibition
Organophosphorus compounds (OPs) have applications in agriculture (e.g., pesticides), industry (e.g., flame retardants), and chemical warfare (nerve agents). In high doses or chronic exposure, they can be toxic or lethal. The primary mechanism, common among all OPs, that initiates their toxic effects is the inhibition of acetylcholinesterase. In acute OP exposure, the subsequent surge of acetylcholine in cholinergic synapses causes a peripheral cholinergic crisis and status epilepticus (SE), either of which can lead to death. If death is averted without effective seizure control, long-term brain damage ensues. This review describes the mechanisms by which elevated acetylcholine can cause respiratory failure and trigger SE; the role of the amygdala in seizure initiation; the role of M1 muscarinic receptors in the early stages of SE; the neurotoxic pathways activated by SE (excitotoxicity/Ca++ overload/oxidative stress, neuroinflammation); and neurotoxic mechanisms linked to low-dose, chronic exposure (Ca++ dyshomeostasis/oxidative stress, inflammation), which do not depend on SE and do not necessarily involve acetylcholinesterase inhibition. The evidence so far indicates that brain damage from acute OP exposure is a direct result of SE, while the neurotoxic mechanisms activated by low-dose chronic exposure are independent of SE and may not be associated with acetylcholinesterase inhibition.
- Open Access
Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus
Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised questions about the neuroprotective efficacy of benzodiazepines. Here, we compared the antiseizure and neuroprotective efficacy of MDZ (5 mg/kg) with that of tezampanel (LY293558; 10 mg/kg), an AMPA/GluK1 receptor antagonist, administered 1 h after injection of the nerve agent, soman (1.2 × LD50), in adult male rats. Both of the anticonvulsants promptly stopped SE, with MDZ having a more rapid effect. However, SE reoccurred to a greater extent in the MDZ-treated group, resulting in a significantly longer total duration of SE within 24 h post-exposure compared with the LY293558-treated group. The neuroprotective efficacy of the two drugs was studied in the basolateral amygdala, 30 days post-exposure. Significant neuronal and inter-neuronal loss, reduced ratio of interneurons to the total number of neurons, and reduction in spontaneous inhibitory postsynaptic currents accompanied by increased anxiety were found in the MDZ-treated group. The rats treated with LY293558 did not differ from the control rats (not exposed to soman) in any of these measurements. Thus, LY293558 has significantly greater efficacy than midazolam in protecting against prolonged seizures and brain damage caused by acute nerve agent exposure.
Open AccessAntiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus
Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised questions about the neuroprotective efficacy of benzodiazepines. Here, we compared the antiseizure and neuroprotective efficacy of MDZ (5 mg/kg) with that of tezampanel (LY293558; 10 mg/kg), an AMPA/GluK1 receptor antagonist, administered 1 h after injection of the nerve agent, soman (1.2 × LD50), in adult male rats. Both of the anticonvulsants promptly stopped SE, with MDZ having a more rapid effect. However, SE reoccurred to a greater extent in the MDZ-treated group, resulting in a significantly longer total duration of SE within 24 h post-exposure compared with the LY293558-treated group. The neuroprotective efficacy of the two drugs was studied in the basolateral amygdala, 30 days post-exposure. Significant neuronal and inter-neuronal loss, reduced ratio of interneurons to the total number of neurons, and reduction in spontaneous inhibitory postsynaptic currents accompanied by increased anxiety were found in the MDZ-treated group. The rats treated with LY293558 did not differ from the control rats (not exposed to soman) in any of these measurements. Thus, LY293558 has significantly greater efficacy than midazolam in protecting against prolonged seizures and brain damage caused by acute nerve agent exposure.
- 1 November 2021
- Published by Elsevier in Brain Research
- Vol. 1770, 147628
Increased inhibitory activity in the basolateral amygdala and decreased anxiety during estrus: A potential role for ASIC1a channels
- 1 November 2021
- Published by Elsevier in Brain Research
- Vol. 1770, 147628
Increased inhibitory activity in the basolateral amygdala and decreased anxiety during estrus: A potential role for ASIC1a channels
- 1 March 2018
- Published by Elsevier in Neuroscience
- Vol. 373, 145-158
Oscillatory Synchronous Inhibition in the Basolateral Amygdala and its Primary Dependence on NR2A-containing NMDA Receptors
- 1 March 2018
- Published by Elsevier in Neuroscience
- Vol. 373, 145-158
Oscillatory Synchronous Inhibition in the Basolateral Amygdala and its Primary Dependence on NR2A-containing NMDA Receptors
- 1 January 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 360 (1) , 23-32
The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala
Exposure to organophosphorus toxins induces seizures that progress to status epilepticus (SE), which can cause brain damage or death. Seizures are generated by hyperstimulation of muscarinic receptors, subsequent to inhibition of acetylcholinesterase; this is followed by glutamatergic hyperactivity, which sustains and reinforces seizure activity. It has been unclear which muscarinic receptor subtypes are involved in seizure initiation and the development of SE in the early phases after exposure. Here, we show that pretreatment of rats with the selective M1 receptor antagonist, VU0255035 [N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)-benzo[c][1,2,5]thiadiazole-4 sulfonamide], significantly suppressed seizure severity and prevented the development of SE for about 40 minutes after exposure to paraoxon or soman, suggesting an important role of the M1 receptor in the early phases of seizure generation. In addition, in in vitro brain slices of the basolateral amygdala (a brain region that plays a key role in seizure initiation after nerve agent exposure), VU0255035 blocked the effects produced by bath application of paraoxon—namely, a brief barrage of spontaneous inhibitory postsynaptic currents, followed by a significant increase in the ratio of the total charge transferred by spontaneous excitatory postsynaptic currents over that of the inhibitory postsynaptic currents. Furthermore, paraoxon enhanced the hyperpolarization-activated cation current Ih in basolateral amygdala principal cells, which could be one of the mechanisms underlying the increased glutamatergic activity, an effect that was also blocked in the presence of VU0255035. Thus, selective M1 antagonists may be an efficacious pretreatment in contexts in which there is risk for exposure to organophosphates, as these antagonists will delay the development of SE long enough for medical assistance to arrive.
- 1 January 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 360 (1) , 23-32
The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala
Exposure to organophosphorus toxins induces seizures that progress to status epilepticus (SE), which can cause brain damage or death. Seizures are generated by hyperstimulation of muscarinic receptors, subsequent to inhibition of acetylcholinesterase; this is followed by glutamatergic hyperactivity, which sustains and reinforces seizure activity. It has been unclear which muscarinic receptor subtypes are involved in seizure initiation and the development of SE in the early phases after exposure. Here, we show that pretreatment of rats with the selective M1 receptor antagonist, VU0255035 [N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)-benzo[c][1,2,5]thiadiazole-4 sulfonamide], significantly suppressed seizure severity and prevented the development of SE for about 40 minutes after exposure to paraoxon or soman, suggesting an important role of the M1 receptor in the early phases of seizure generation. In addition, in in vitro brain slices of the basolateral amygdala (a brain region that plays a key role in seizure initiation after nerve agent exposure), VU0255035 blocked the effects produced by bath application of paraoxon—namely, a brief barrage of spontaneous inhibitory postsynaptic currents, followed by a significant increase in the ratio of the total charge transferred by spontaneous excitatory postsynaptic currents over that of the inhibitory postsynaptic currents. Furthermore, paraoxon enhanced the hyperpolarization-activated cation current Ih in basolateral amygdala principal cells, which could be one of the mechanisms underlying the increased glutamatergic activity, an effect that was also blocked in the presence of VU0255035. Thus, selective M1 antagonists may be an efficacious pretreatment in contexts in which there is risk for exposure to organophosphates, as these antagonists will delay the development of SE long enough for medical assistance to arrive.
- 1 November 2015
- Published by Elsevier in Experimental Neurology
- Vol. 273, 11-23
GABAergic interneuronal loss and reduced inhibitory synaptic transmission in the hippocampal CA1 region after mild traumatic brain injury
- 1 November 2015
- Published by Elsevier in Experimental Neurology
- Vol. 273, 11-23
GABAergic interneuronal loss and reduced inhibitory synaptic transmission in the hippocampal CA1 region after mild traumatic brain injury
- 1 September 2014
- Published by Elsevier in NeuroToxicology
- Vol. 44, 335-343
Pathophysiological mechanisms underlying increased anxiety after soman exposure: Reduced GABAergic inhibition in the basolateral amygdala
- 1 September 2014
- Published by Elsevier in NeuroToxicology
- Vol. 44, 335-343
Pathophysiological mechanisms underlying increased anxiety after soman exposure: Reduced GABAergic inhibition in the basolateral amygdala